Abcam plc

Abcam plc is a provider of protein research tools and services, with an unrivaled range of products and expert technical support, enabling scientists to analyze living cells at the molecular level and improving the understanding of health and disease. To find out more, please visit www.abcam.com.

Discover more with Abcam’s in-house technologies:

Multiplex miRNA profiling made easy with Firefly™ particle technology

MicroRNA (miRNA) profiling holds great potential for the discovery and detection of miRNA biomarkers, both for cancer research and diagnosis.  Researchers need to be able to conveniently and cost-effectively measure many miRNAs simultaneously within multiple samples. While qPCR provides a good solution for detecting single miRNAs, this approach is labor intensive when measuring multiple miRNAs, particularly for large sample sets. Techniques such as RNA-seq and microarrays can handle multiple miRNA detection, but involve challenging data analysis and do not scale well as sample number increases. The Firefly™ assay technology enables multiplex miRNA profiling with high sensitivity, high throughput and ease of workflow.

Developed by MIT alumni, Firefly multiplex assay technology enables rapid detection of up to 68 miRNAs across a large number of samples, supporting miRNA detection direct from crude biofluids. This technology uses proprietary hydrogel particles that enhance assay sensitivity and can be read using standard flow cytometers. Highlighted benefits include:

• Fully customizable – multiplex up to 68 targets in every single well

• Sensitive – detects miRNAs from as little as 100 pg purified RNA or 10 μl crude biofluid

• Ease of use – simplified workflow and readout on standard flow cytometers

Firefly’s technology has already been referenced in papers published in leading journals. This technology shows great potential for improving cancer research and diagnosis.

Redefining antibody quality with RabMAb® technology

Antibodies represent a significant amount of time and resource for researchers. Antibody quality is a strongly debated issue in the scientific community.  Low quality antibodies can lead to irreproducible results and delay scientific discovery. There is an ongoing need for increased quality. The market is looking for more sensitive and specific validated antibodies with consistent reproducibility and easy scalability.

RabMAb® primary antibodies combine the superior antigen recognition of a rabbit antibody with the specificity and consistency of a monoclonal for use in research, diagnostic and therapeutic applications. Incorporating extensive batch validation and recombinant monoclonal production, RabMAb primary antibodies deliver low risk, highly reproducible results which are ideal for multiple platforms and applications.  Highlighted benefits include:

• Ultra-sensitivity – accurately detect and quantify proteins including those with low abundance and/or small epitopes

• Recombinant monoclonal production – enables consistency throughout studies from recombinant scalable production with high specificity and no batch to batch variation

• Batch-validated – consistent low risk working across multiple platforms and applications

For last 18+ years, RabMAb technology has been helping to drive forward scientific discovery in 550+ institutions and 150+ pharma and biotech companies.

Reliable, quick results with SimpleStep ELISA® kits

The Enzyme-Linked Immunosorbent Assay (ELISA) has been a mainstay technique for target protein quantitation for over 40 years because it offers superior sensitivity and specificity with minimal sample preparation compared to other techniques. Finding the right kit is not always easy: higher sensitivity, specificity and accuracy are common requirements for researchers using ELISA.

The SimpleStep ELISA platform improves on the conventional ELISA by providing sensitive and specific quantification in one simple step, delivering trusted results in less than 90 minutes.

Discover more at abcam.com/simplestep.  Highlighted benefits include:

• Sensitive – With a linear range encompassing physiological target protein concentrations, the assay has been demonstrated to reproducibly and accurately measure the concentration of the analyte in relevant biological samples.

• Specific – antibodies from a large antibody candidate pool are tested pairwise in an ELISA matrix as both capture and detector antibodies. Only antibody combinations that give the highest overall signal are used for further development.

• Fast – A single antibody analyte complex formation step in place of a multi-step process allows the assay to be completed in 90 minutes with the same or better performance as a standard ELISA.

Many labs globally have been convinced by the benefits of SimpleStep ELISA, selecting it as their assay of choice for reliable results.